Prescribing for Dry Eye Disease

The Tear Film and Ocular Surface Society (TFOS) Dry Eye Workshop (DEWS) III report, which was recently released, includes an updated prescribing algorithm based on DED etiology or pathogenic drivers.

By
LISA HORNICK, OD, MBA, FAAO
July 1, 2025
7 min

Optometric Management

1

The TFOS DEWS III report categorizes dry eye disease (DED) into three main drivers: tear film deficiencies, eyelid abnormalities, and ocular surface abnormalities.
2

A targeted treatment approach based on the main cause of DED is recommended, utilizing therapies like artificial tears, lid hygiene, and ocular surface regenerators.
3

Meibomian gland dysfunction (MGD) is a primary cause of evaporative DED, requiring evidence-based therapies such as vitamin D3 and in-office tear stimulation.
4

Anatomic misalignment and neural dysfunction can contribute to DED, with potential surgical interventions and treatments like moisture chamber goggles for severe cases.
5

Lifestyle factors, including sleep, diet, and mental health, significantly impact DED, necessitating patient education on these aspects for effective management.

Prescribing for Dry Eye Disease

1

2

3

4

5

Original Source(s)

Prescribing for Dry Eye Disease

Related Content

Mapping Clinical Evidence from Randomized Controlled Trials on Acupuncture and Moxibustion for the Management of Dry Eye Disease

Incomplete rather than complete nasolacrimal duct obstruction Is strongly associated with meibomian gland dysfunction in postmenopausal women with PANDO: a cross-sectional study

AI Enhances Meibomian Gland Detection